Abstract
The study included evaluation of respiratory function, bronchial conductivity, gas homeostasis, and 24-hour profile of blood pressure (BP) in 15 male patients with chronic obstructive lung disease and I-II stage arterial hypertension prior to and after 2 weeks of therapy with telmisartan. The drug, administered in a dose of 80 mg/day, significantly increased 1 sec forced expiratory volume, peak expiratory flow rate, decreased effective bronchial resistance and CO2 partial pressure in arterial blood. Telmisartan also significantly reduced mean systolic BP (SBP) (p < 0.003) and diastolic BP (DBP) (p < 0.001) during day hours, SBD (p < 0.01) and pulse BP (p < 0.05) during night hours, significantly reduced SBP load (p < 0.02) and DBP load (p < 0.003) during day hours, and SBP load during night hours (p < 0.02).
MeSH terms
-
Aged
-
Airway Resistance / drug effects
-
Angiotensin II Type 1 Receptor Blockers / administration & dosage
-
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
-
Benzimidazoles / administration & dosage
-
Benzimidazoles / therapeutic use*
-
Benzoates / administration & dosage
-
Benzoates / therapeutic use*
-
Blood Pressure / drug effects
-
Circadian Rhythm
-
Dose-Response Relationship, Drug
-
Forced Expiratory Flow Rates / drug effects
-
Humans
-
Hypertension / complications
-
Hypertension / drug therapy*
-
Hypertension / physiopathology
-
Male
-
Middle Aged
-
Pulmonary Disease, Chronic Obstructive / complications
-
Pulmonary Disease, Chronic Obstructive / drug therapy*
-
Pulmonary Disease, Chronic Obstructive / physiopathology
-
Telmisartan
-
Treatment Outcome
Substances
-
Angiotensin II Type 1 Receptor Blockers
-
Benzimidazoles
-
Benzoates
-
Telmisartan